Published in J Biol Chem on December 05, 2001
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65
Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell (2009) 2.57
Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet (2011) 2.34
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet (2003) 1.85
Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med (2010) 1.72
Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci (2008) 1.59
Energy deficit in Huntington disease: why it matters. J Clin Invest (2011) 1.51
Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet (2011) 1.48
Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci (2008) 1.48
Huntingtin Subcellular Localisation Is Regulated by Kinase Signalling Activity in the StHdhQ111 Model of HD. PLoS One (2015) 1.40
Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev (2009) 1.37
Altered aggregation properties of mutant gamma-crystallins cause inherited cataract. EMBO J (2002) 1.35
Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener (2006) 1.35
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx (2005) 1.33
Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 1.25
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta (2011) 1.16
Mechanisms directing the nuclear localization of the CtBP family proteins. Mol Cell Biol (2006) 1.13
Targeting Huntington's disease through histone deacetylases. Clin Epigenetics (2011) 1.13
Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc Natl Acad Sci U S A (2003) 1.11
Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem (2009) 1.10
Binding with nucleic acids or glycosaminoglycans converts soluble protein oligomers to amyloid. J Biol Chem (2011) 1.04
Role of the C-terminal binding protein PXDLS motif binding cleft in protein interactions and transcriptional repression. Mol Cell Biol (2006) 1.04
Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. PLoS One (2010) 1.02
Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics (2011) 1.00
Genetics and neuropathology of Huntington's disease. Int Rev Neurobiol (2011) 0.99
Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective. Mol Neurobiol (2014) 0.96
Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci U S A (2003) 0.96
Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation. EMBO J (2015) 0.95
Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors. J Med Genet (2009) 0.93
Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts. BMC Neurosci (2008) 0.92
Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease. Hum Mol Genet (2010) 0.92
The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol Med (2013) 0.91
The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx (2004) 0.91
The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition. Front Neuroanat (2011) 0.90
MeCP2: a novel Huntingtin interactor. Hum Mol Genet (2013) 0.89
Huntington's Disease and Striatal Signaling. Front Neuroanat (2011) 0.86
Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells. Mol Cell Neurosci (2008) 0.86
Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol (2007) 0.86
Huntington's disease: the past, present, and future search for disease modifiers. Yale J Biol Med (2013) 0.85
C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer. Int J Cell Biol (2013) 0.84
Native mutant huntingtin in human brain: evidence for prevalence of full-length monomer. J Biol Chem (2012) 0.84
Huntingtin localisation studies - a technical review. PLoS Curr (2011) 0.82
Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease. Hum Mol Genet (2015) 0.82
Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy. Int J Biomed Sci (2011) 0.82
A Drosophila model of the neurodegenerative disease SCA17 reveals a role of RBP-J/Su(H) in modulating the pathological outcome. Hum Mol Genet (2011) 0.82
Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. J Neurol (2006) 0.81
Replacement of huntingtin exon 1 by trans-splicing. Cell Mol Life Sci (2012) 0.80
Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cell Mol Neurobiol (2016) 0.78
Transcriptome sequencing reveals aberrant alternative splicing in Huntington's disease. Hum Mol Genet (2016) 0.78
Studying polyglutamine diseases in Drosophila. Exp Neurol (2015) 0.76
An Intein-based Strategy for the Production of Tag-free Huntingtin Exon 1 Proteins Enables New Insights into the Polyglutamine Dependence of Httex1 Aggregation and Fibril Formation. J Biol Chem (2016) 0.76
Pleomorphic Invasive Ductal Carcinoma of the Breast in a Patient with Huntington's Disease. Case Rep Pathol (2014) 0.75
Age-associated chromatin relaxation is enhanced in Huntington's disease mice. Aging (Albany NY) (2017) 0.75
Transgenic rat model of Huntington's disease: a histopathological study and correlations with neurodegenerative process in the brain of HD patients. Biomed Res Int (2014) 0.75
CAG Expansions Are Genetically Stable and Form Nontoxic Aggregates in Cells Lacking Endogenous Polyglutamine Proteins. MBio (2016) 0.75
Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases. Biophys Rev (2014) 0.75
Comparison of modules of wild type and mutant Huntingtin and TP53 protein interaction networks: implications in biological processes and functions. PLoS One (2013) 0.75
Huntington's disease and mitochondrial alterations: emphasis on experimental models. J Bioenerg Biomembr (2010) 0.75
Nuclear localization of huntingtin during spermatogenesis. Neurol Sci (2013) 0.75
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy (2005) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci U S A (2005) 2.72
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Biological aspect of hyperthymic temperament: light, sleep, and serotonin. Psychopharmacology (Berl) (2010) 2.35
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab (2007) 2.31
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet (2010) 2.23
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet (2003) 2.08
Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med (2004) 1.93
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nat Methods (2005) 1.83
Control of petal shape and floral zygomorphy in Lotus japonicus. Proc Natl Acad Sci U S A (2006) 1.78
Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways. Autophagy (2008) 1.78
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol (2008) 1.69
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Self-assembly of the plant cell wall requires an extensin scaffold. Proc Natl Acad Sci U S A (2008) 1.67
Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem (2009) 1.64
Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem (2010) 1.62
B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol (2011) 1.59
Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA (2011) 1.59
Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem (2002) 1.56
The in vivo gene expression signature of oxidative stress. Physiol Genomics (2008) 1.55
Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest (2011) 1.54
Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem (2005) 1.53
Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51
The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann Neurol (2010) 1.45
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Molecular mechanism and regulation of autophagy. Acta Pharmacol Sin (2005) 1.40
Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis (2010) 1.39
Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36
Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol (2008) 1.36
Daxx silencing sensitizes cells to multiple apoptotic pathways. Mol Cell Biol (2003) 1.35
Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J Biol Chem (2004) 1.35
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
Autophagy regulates endoplasmic reticulum stress in ischemic preconditioning. Autophagy (2012) 1.34
Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34
Identification of ANKRD11 as a p53 coactivator. J Cell Sci (2008) 1.33
Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol (2011) 1.32
Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol (2004) 1.30
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29
Autophagy activation is associated with neuroprotection in a rat model of focal cerebral ischemic preconditioning. Autophagy (2010) 1.28
Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci (2004) 1.27
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26
Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 1.26
Molecular analysis of virulent determinants of enterovirus 71. PLoS One (2011) 1.25
Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum Mol Genet (2012) 1.25
Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle (2011) 1.25
High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 1.24